Cabotegravir User Reviews & Ratings
Brand names: Apretude, Vocabria
Cabotegravir has an average rating of 9.0 out of 10 from a total of 2 reviews on Drugs.com. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Pre-Exposure Prophylaxis | 2 reviews for Pre-Exposure Prophylaxis | 4 medications |
- win...
- Taken for 6 months to 1 year
- September 5, 2024
For Pre-Exposure Prophylaxis "I've had no problem with this med. Been on it for almost a year. I use it as PrEP. But your bottom is sore for a minute, but it goes away quickly. Overall, I give it an 8/10."
Are you taking this medicine?
Your review helps others make informed decisions.Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about cabotegravir
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: integrase strand transfer inhibitor
- Breastfeeding
- En español
Patient resources
- Cabotegravir drug information
- Cabotegravir (Intramuscular) (Advanced Reading)
- Cabotegravir (Oral) (Advanced Reading)
For Pre-Exposure Prophylaxis "I like it so much better than the Truvada I was on before. There is a lot of peace of mind with not having to wonder if you took it or not this morning, especially if there is a lot of variation in your life or if you are not a creature of habit, and it's not easy to establish a routine that strict. I feel zero pain or discomfort at the injection site and have never had any side effects. The downside is having to go to the Dr. four more times per year. I started taking Truvada because it was near total protection, but that means I need near total protection for me, not in theory for someone perfect. Apretude gives me that."